Alzheimer’s Association commits $100 million to test whether adding a drug to a prevention program provides extra protection against dementia
Alzheimer’s Association commits $100 million to test whether adding a drug to a prevention program provides extra protection against dementia
The new three-year PROTECT-Cog project will compare two versions of a program designed to prevent cognitive decline and test the addition of a drug that affects metabolism and immune function. GLP-1 receptor agonists, a class that includes semaglutide, are among the possible options. The organizers have not named a specific drug.
On July 13, the Alzheimer’s Association announced PROTECT-Cog, a $100 million global study. Participants at increased risk of cognitive decline will receive one of two versions of the same program: a comprehensive version with regular support, or a lighter version that covers the same material but involves fewer contacts. Researchers will then test whether adding a drug changes the outcome.
The program grew out of U.S. POINTER, a study of 2 111 Americans aged 60–79 who already had risk factors, including physical inactivity, poor diet, metabolic problems, or a family history of memory impairment. Participants in both groups exercised, changed their diets, engaged in cognitive training, maintained social activity, and monitored blood pressure and other health measures.
The difference was how the support was organized. Over two years, the intensive group had 38 meetings with support staff, while the lighter group had six. In the JAMA article, both groups improved their cognitive test scores, and the intensive group performed better than the lighter group. U.S. POINTER showed the difference between advising people to change their lifestyle and providing a program in which someone helps them turn those changes into regular practice.
U.S. POINTER measured changes in cognitive test performance. Two thousand participants and two years of follow-up are not enough to estimate a rare outcome, namely new cases of dementia, with confidence. The study also had no group that received no intervention. PROTECT-Cog will follow participants for three years and conduct detailed assessments every six months.
GLP-1 agonists mimic a gut hormone that increases insulin secretion after a meal and affects appetite and metabolism. The evidence linking them to brain outcomes remains weaker than the evidence for their effects on blood glucose and weight. A meta-analysis of 26 randomized trials involving 164 thousand participants found a lower combined risk of dementia or cognitive impairment with this drug class. However, only 212 such events occurred across all the studies, and the authors did not find a separate statistically significant reduction in the risk of Alzheimer’s disease.
PROTECT-Cog will test the drug against a more demanding comparison: whether it provides additional protection when physical activity, nutrition, sleep, vascular risk management, and social engagement are already integrated into a functioning program. This design will help separate the effect of the drug itself from the effects of support, scheduling, and regular participation.